ftd

Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a novel oral combination drug containing trifluridine (TFT) and tipiracil hydrochloride (TTP) in a 2:1 molar ratio.

HSDAVFTDNYTRLRRQLAVRRYLNSILN-NH2 is a peptide with anti-inflammatory properties [1].

G923-0271 is a TDP-43 inhibitor that improves disease phenotypes in TDP-43 nematode models and reduces the overexpression of human TDP-43 at the cellular level, making it useful for studying diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

RNA binder 1 (Compound 4b) is an RNA-binding agent capable of crossing the blood-brain barrier. It selectively binds to the G-quadruplex structure of the G4C2 repeat sequence RNA of the C9orf72 gene. This compound significantly reduces levels of the toxic polypeptides poly(GA) and poly(GP) in cells derived from amyotrophic lateral sclerosis (ALS) patients, while it has no significant impact on the antisense polypeptide poly(PR), demonstrating selectivity for sense RNA. RNA binder 1 is useful for studying ALS and frontotemporal dementia (FTD).

Di-Ellipticine-RIBOTAC is a bifunctional small molecule that effectively diminishes the r(G4C2) repeat expansion associated with c9ALS/FTD both in vitro and in vivo, showcasing therapeutic potential in amyotrophic lateral sclerosis (ALS) models.